Get In Touch
Have any questions or comments about the content you see on this page?
Our News
August 9, 2023
Paul Nioi, PhD, VP of Discovery and Translational Research and Head of Alnylam Human Genetics recently spoke with European Medical Review editor Caroline Peachey on The European Medical Review Podcast. Paul discussed the differences between and advantages of RNA interference (RNAi) versus traditional approaches to drug development, how Alnylam has overcome the challenges of delivery to different tissues, and the RNAi therapeutic drug development landscape. He and Caroline also talked about the manufacturing of RNAi therapeutics and where RNAi therapeutics fit into the broader landscape of precision medicines. To dig deeper, learn more about how genetics is driving discovery of Alnylam's next wave of RNAi therapeutics and the the science of RNAi.
Listen to the episode here.
Have any questions or comments about the content you see on this page?
The following content may not be associated with Alnylam Pharmaceuticals.
Links to all outside sites are provided as a reference for our visitors.
Alnylam Pharmaceuticals does not endorse and is not responsible for the content on sites that are not owned and operated by Alnylam Pharmaceuticals.
Proceed to Site